Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of "Buy" by Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have been given a consensus recommendation of "Buy" by the nine research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $218.63.

KRYS has been the subject of several recent research reports. Chardan Capital reissued a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a research report on Wednesday. Guggenheim reduced their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday. HC Wainwright restated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 6th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective on the stock. Finally, Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at $2,208,472.88. The trade was a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC raised its holdings in shares of Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after buying an additional 21,133 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after buying an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after buying an additional 6,600 shares during the last quarter. Hood River Capital Management LLC raised its holdings in shares of Krystal Biotech by 2.1% in the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after buying an additional 10,622 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Krystal Biotech by 16.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after buying an additional 71,200 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Down 3.6%

KRYS stock traded down $4.94 during midday trading on Tuesday, hitting $132.23. The company's stock had a trading volume of 329,798 shares, compared to its average volume of 300,407. Krystal Biotech has a 52-week low of $131.71 and a 52-week high of $219.34. The firm has a market capitalization of $3.82 billion, a P/E ratio of 44.22 and a beta of 0.79. The firm has a 50-day simple moving average of $171.56 and a 200-day simple moving average of $170.01.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million. On average, sell-side analysts expect that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).